Epoetin

Phase 3Small molecule

Roche

Epoetin is one of 69 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Epoetin

Roche

Phase 3

1 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Flomax

Epoetin Beta

5 9

Genotropin

EMD Serono

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia5 trials

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Completed· Roche logo

Roche·Phase 3·NCT00077597·182 enrolled

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Completed· Roche logo

Roche·Phase 3·NCT00546481·80 enrolled

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Completed· Roche logo

Roche·Phase 3·NCT00077623·572 enrolled

Show 2 more trials

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Completed· Roche logo

Roche·Phase 3·NCT00077610·673 enrolled

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Completed· Roche logo

Roche·Phase 3·NCT00081484·336 enrolled

Dialysis Patients1 trial

Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial

Completed·GGeneral Hospital Sveti Duh·Phase 3·NCT00322413·80 enrolled

Erythropoietin1 trial

Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1·NCT00491413·15 enrolled

Chronic Kidney Disease1 trial

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

Completed· Takeda logo

Takeda·Phase 3·NCT01478971·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Epoetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epoetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epoetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Epoetin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia5 trials

Dialysis Patients1 trial

Erythropoietin1 trial

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News